Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow these two dose schedules sit alongside each other, and why the comparison is more complicated than it looks
The decision you are actually trying to make
If you are weighing up Mounjaro against Wegovy, or considering switching between them, 7.5 mg is often the point where that question sharpens. It sits in the middle of Mounjaro's licensed range, above the starter doses that exist mainly to ease your system in, and below the higher doses where the strongest trial results were recorded. People at 7.5 mg are typically well past the settling-in phase and seeing meaningful appetite changes.
The natural question is: if I moved to Wegovy, where would I land? Our page on what dose of Wegovy is equivalent to 7.5 mg Mounjaro explores that question in detail, though the honest answer is that nobody can tell you from a table alone. Semaglutide's standard maintenance dose is 2.4 mg weekly. That is the dose studied in the STEP 1 trial, which found an average body-weight reduction of around 15% over 68 weeks, as reported in the New England Journal of Medicine. Tirzepatide at its highest doses produced greater average losses than semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial. But 7.5 mg is not the highest tirzepatide dose (it is the midpoint) so drawing a clean comparison gets even harder.
The most useful framing is not "what is the equivalent dose" but "which medicine, at which dose, is right for me given my health picture". That is what a prescriber works through with you. You can read more about the broader differences on our Wegovy vs Mounjaro comparison page.
What the dose schedules actually look like side by side
Laying the ladders out factually makes the gap in logic clearer. Mounjaro's licensed UK strengths run from 2.5 mg up through 5, 7.5, 10, 12.5 and 15 mg, typically increased every four weeks by the prescriber. Wegovy's standard path runs 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, a completely different numerical scale. The MHRA also approved a higher 7.2 mg Wegovy dose in early 2026 and a dedicated single-dose 7.2 mg pen in April 2026, which in trials produced around 20.7% average weight loss over 72 weeks, beginning to approach tirzepatide 15 mg territory.
The table below sets out the key factual comparisons. Numbers are drawn from the published trial evidence and UK regulatory sources; they describe populations, not predictions for any individual.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Standard maintenance dose (UK) | Up to 15 mg weekly | 2.4 mg weekly (7.2 mg also licensed) |
| Average weight loss at highest studied dose (trial populations) | ~20–21% at 15 mg (SURMOUNT-1) | ~15% at 2.4 mg (STEP 1); ~20.7% at 7.2 mg |
| NICE recommendation threshold (England) | BMI ≥35 + ≥1 weight-related comorbidity (TA1026) | BMI ≥35 + ≥1 comorbidity, specialist service, max 2 years (TA875) |
| Injection frequency | Once weekly | Once weekly |
| UK licence status | Weight management + type 2 diabetes | Weight management + cardiovascular risk reduction |
A cost comparison between Mounjaro and Wegovy is worth reading separately, pricing varies by dose and has changed materially since 2025.
Why a milligram conversion table would mislead you
The numbers on the two dose ladders describe amounts of completely different molecules acting on different receptor combinations. Saying "7.5 mg Mounjaro equals X mg Wegovy" is a bit like converting miles to kilograms, the units look similar on a page but they measure different things.
What clinical practice actually looks at when someone moves between these medicines is the therapeutic effect achieved, how well the current medicine was tolerated, any contraindications, and the patient's overall health profile. A prescriber switching someone from 7.5 mg Mounjaro to Wegovy would not simply pick the nearest number; they would consider where the person is in their treatment journey and what dose of semaglutide makes clinical sense to start at. The NHS England guidance on weight management injections makes clear that these decisions sit with the clinical team, not with equivalence guides.
A quick check you can do right now: pull up the GPhC register at pharmacyregulation.org/registers and search for any online pharmacy you are considering. If it is not listed, that is a firm reason to stop. This takes under a minute and is the single most reliable way to confirm you are dealing with a regulated service.
For a closer look at how individual dose pairs compare, our pages on switching dose contexts and on whether Wegovy 2.4 mg sits alongside Mounjaro 2.5 mg cover those specific questions. There is also a page addressing whether 1 mg Wegovy is in the same range as 7.5 mg Mounjaro for those working through the early Wegovy steps.
Which medicine is right for you, and what happens next
NICE has appraised both medicines and recommends each under different conditions. Tirzepatide (TA1026, published December 2024) is recommended for adults with a BMI of 35 or above alongside at least one weight-related comorbidity; semaglutide (TA875) carries the additional requirement that it is used within a specialist weight management service for a maximum of two years. Lower BMI thresholds apply for some ethnic backgrounds under both appraisals. Neither set of criteria is a guarantee of access, clinical suitability is always assessed individually, as the NICE TA1026 recommendations make plain.
At nume, our prescribers review the full clinical picture before any medicine is prescribed. Which suits you, at which dose, is a decision they make with you, not one a page like this can make for you. If you want to explore that, starting a free consultation is the logical next step. You can also read about our clinical team on the clinical oversight page if you want to know more about who would be reviewing your case.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.